Impotence in diabetic and non-diabetic hospital outpatients.

Abstract

recommendations for hydrallazine therapy and previous evidence.1 3 One report is consistent with our experience.5Autoimmune phenomena were also more frequent in asymptomatic slow acetylators receiving 200 mg hydrallazine a day or less.This has previously been reported only in patients taking over 200 mg hydrallazine daily.2Our study indicates that conventionally "safe" doses of hydrallazine may cause both asymptomatic autoimmune phenomena and a lupus syndrome which is not always mild or transient and may require steroids.Potentially serious hydrallazine toxicity is a possibility in all patients taking this drug even after many months of uncomplicated treatment, but especially in slow acetylators in whom constant vigilance for early symptoms is necessary.